Barclays raised the firm’s price target on Idexx Laboratories (IDXX) to $520 from $481 and keeps an Overweight rating on the shares. The company reported a Q4 beat and “healthy” 2025 revenue guidance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- IDEXX Laboratories Reports Strong 2024 Financial Results
- IDEXX Labs Earnings Call Highlights Growth and Innovation
- Early notable gainers among liquid option names on February 3rd
- Morning Movers: Tyson Foods jumps following first quarter results
- Options Volatility and Implied Earnings Moves Today, February 03, 2025